Literature DB >> 1597725

Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer.

W C Buijs1, L F Massuger, R A Claessens, P Kenemans, F H Corstens.   

Abstract

This study reports the biodistribution and dosimetry for a monoclonal antibody against ovarian carcinoma. Eight patients received 140 MBq 111In-OV-TL 3 F(ab')2; thereafter gamma camera imaging was performed daily up to 96 hr. By using the conjugated view counting method, activity in the organs was quantitated by phantom calibration and by whole-body measurements using a whole-body counter with the conjugated view counting method. Red bone marrow uptake was derived from regions of interest over the lumbar vertebrae and iliac crest. In both methods, organ uptake varied only slightly with time, having a mean value of approximately 18%, 4%, 6% and 17% of the injected dose in the liver, spleen, kidneys and red bone marrow, respectively. The mean radiation dose to these organs was 0.9, 1.5, 1.2 and 0.5 mGy/MBq. The effective dose equivalent was 0.4 mSv/MBq. In this study, two different methods of uptake calculations, result in similar values of organ uptake.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597725

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies.

Authors:  M A Plaizier; J C Roos; G J Teule; E B van Dieren; W den Hollander; H J Haisma; R L DeJager; A van Lingen
Journal:  Eur J Nucl Med       Date:  1994-03

2.  Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show no detectable homing to the gut in vivo.

Authors:  J Kelsen; J Agnholt; L Falborg; J T Nielsen; J L Rømer; H J Hoffmann; J F Dahlerup
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

3.  Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue.

Authors:  P J Hammond; A F Wade; M E Gwilliam; A M Peters; M J Myers; S G Gilbey; S R Bloom; J Calam
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

4.  Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.

Authors:  Liza Lindenberg; Anish Thomas; Stephen Adler; Esther Mena; Karen Kurdziel; Julia Maltzman; Bruce Wallin; Kimberly Hoffman; Ira Pastan; Chang Hum Paik; Peter Choyke; Raffit Hassan
Journal:  Oncotarget       Date:  2015-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.